Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

The TP53 gene polymorphisms and survival of sporadic breast cancer patients.

Bišof V, Salihović MP, Narančić NS, Skarić-Jurić T, Jakić-Razumović J, Janićijević B, Rudan P.

Med Oncol. 2012 Jun;29(2):472-8. doi: 10.1007/s12032-011-9875-2. Epub 2011 Mar 2.

PMID:
21365326
2.

Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival.

Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimäki A, von Smitten K, Aittomäki K, Heikkilä P, Blomqvist C, Nevanlinna H.

Clin Cancer Res. 2005 Jul 15;11(14):5098-103.

3.

XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer.

Tengström M, Mannermaa A, Kosma VM, Hirvonen A, Kataja V.

Anticancer Res. 2014 Jun;34(6):3031-7.

PMID:
24922669
4.

High TIMM17A expression is associated with adverse pathological and clinical outcomes in human breast cancer.

Salhab M, Patani N, Jiang W, Mokbel K.

Breast Cancer. 2012 Apr;19(2):153-60. doi: 10.1007/s12282-010-0228-3. Epub 2010 Oct 23.

PMID:
20972741
5.

TP53 gene polymorphisms and breast cancer in Croatian women: a pilot study.

Bisof V, Salihović MP, Narancić NS, Skarić-Jurić T, Jakić-Razumović J, Janićijević B, Turek S, Rudan P.

Eur J Gynaecol Oncol. 2010;31(5):539-44.

PMID:
21061796
6.

Allelic loss on distal chromosome 17p is associated with poor prognosis in a group of Brazilian breast cancer patients.

Nagai MA, Pacheco MM, Brentani MM, Marques LA, Brentani RR, Ponder BA, Mulligan LM.

Br J Cancer. 1994 Apr;69(4):754-8.

7.

Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.

Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S.

J Clin Pathol. 2008 Mar;61(3):327-32. Epub 2007 Nov 23.

PMID:
18037662
8.

Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer.

Hrstka R, Beranek M, Klocova K, Nenutil R, Vojtesek B.

Oncol Rep. 2009 Nov;22(5):1205-11.

PMID:
19787241
9.

Locoregional recurrence of breast cancer: a retrospective comparison of treatment methods.

Skowronek J, Piotrowski T.

Neoplasma. 2002;49(6):426-31.

PMID:
12584593
10.

High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.

Shubbar E, Helou K, Kovács A, Nemes S, Hajizadeh S, Enerbäck C, Einbeigi Z.

BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.

11.

Can a phenotype for recessive inheritance in breast cancer be defined?

Ellberg C, Jönsson G, Olsson H.

Fam Cancer. 2010 Dec;9(4):525-30. doi: 10.1007/s10689-010-9355-4.

PMID:
20549370
12.

Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?

Weissenbacher TM, Zschage M, Janni W, Jeschke U, Dimpfl T, Mayr D, Rack B, Schindlbeck C, Friese K, Dian D.

Breast Cancer Res Treat. 2010 Jul;122(1):27-34. doi: 10.1007/s10549-010-0917-9. Epub 2010 May 8. Review.

PMID:
20454925
13.

TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy.

Henríquez-Hernández LA, Pérez LF, Hernández AG, de León AC, Díaz-Chico B, Rosales AM.

Cancer Epidemiol. 2010 Aug;34(4):490-3. doi: 10.1016/j.canep.2010.03.004. Epub 2010 Apr 3.

PMID:
20371218
14.

Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients.

Tong D, Heinze G, Pils D, Wolf A, Singer CF, Concin N, Hofstetter G, Schiebel I, Rudas M, Zeillinger R.

BMC Cancer. 2010 Dec 15;10:682. doi: 10.1186/1471-2407-10-682.

15.

LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.

Kyndi M, Alsner J, Hansen LL, Sørensen FB, Overgaard J.

Acta Oncol. 2006;45(5):602-9.

PMID:
16864176
16.

Medial tumor localization in breast cancer--an unappreciated risk factor?

Bräutigam E, Track C, Seewald DH, Feichtinger J, Spiegl K, Hammer J.

Strahlenther Onkol. 2009 Oct;185(10):663-8. doi: 10.1007/s00066-009-1984-x. Epub 2009 Oct 6.

PMID:
19806331
17.

High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.

Tokunaga E, Okada S, Yamashita N, Akiyoshi S, Kitao H, Morita M, Kakeji Y, Maehara Y.

Breast Cancer. 2012 Apr;19(2):161-9. doi: 10.1007/s12282-010-0232-7. Epub 2010 Nov 10.

PMID:
21063923
18.

Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer.

Grönberg M, Fjällskog ML, Jirström K, Janson ET.

Acta Oncol. 2012 Mar;51(3):386-93. doi: 10.3109/0284186X.2011.631576. Epub 2011 Nov 9.

PMID:
22067021
19.

Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period.

Fortunato L, Mascaro A, Poccia I, Andrich R, Amini M, Costarelli L, Cortese G, Farina M, Vitelli C.

Ann Surg Oncol. 2012 Apr;19(4):1107-14. doi: 10.1245/s10434-011-1907-9. Epub 2011 Sep 13.

PMID:
21913022
20.

Prognostic analysis of survival in small breast cancers.

Mustafa IA, Cole B, Wanebo HJ, Bland KI, Chang HR.

J Am Coll Surg. 1998 May;186(5):562-9.

PMID:
9583697

Supplemental Content

Support Center